TMDX - NASDAQ
TransMedics Group, Inc.
$69.69
+3.2%TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
At a Glance
Live Snapshottmdx
Total Non-Current Assets
Last Annual Value
430.59M
3-Year CAGR
159%
5-Year CAGR
141%
10-Year CAGR
69%
TransMedics Group, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TransMedics Group, Inc. NASDAQ:TMDX | 430.59M | 30.1% | 92.7% | 69.2% | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 55.51M | 39.8% | 95.1% | N/A | |
 Glaukos Corporation NYSE:GKOS | 418.50M | -8.4% | -8.2% | 40.1% | |
 Bruker Corporation NASDAQ:BRKR | 4.03B | 24.5% | 27.9% | 22.3% | |
 Hinge Health, Inc. NYSE:HNGE | 210.86M | 31.5% | N/A | N/A | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 871.60M | 72.3% | 41.3% | N/A | |
 Indivior Pharmaceuticals Inc NASDAQ:INDV | 552.00M | 3.4% | 7.3% | 9.7% | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 93.58M | 573.7% | 146.3% | N/A | |
 Oscar Health, Inc. NYSE:OSCR | 1.71B | 3.8% | 25.2% | N/A | |
 Option Care Health, Inc. NASDAQ:OPCH | 2.19B | -0.7% | -0.2% | 17.6% | |
 Immunovant, Inc. NASDAQ:IMVT | 8.20M | 75.9% | 18.7% | N/A |
TransMedics Group, Inc. Fair Value Envelope
Related Guides
Continue your TMDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.